Robert Azelby

Robert Azelby has an estimated net worth of $9.09 Million. This is based on reported shares across multiple companies, which include Cascadian Therapeutics, Inc., IMMUNOMEDICS INC, ALDER BIOPHARMACEUTICALS INC, Eliem Therapeutics, Inc., Clovis Oncology, Inc., Juno Therapeutics, Inc., CHINOOK THERAPEUTICS, INC., ADC Therapeutics SA, CARDINAL HEALTH INC, Terns Pharmaceuticals, Inc., and Autolus Therapeutics plc.

2018 was Robert Azelby's most active year for acquiring shares with 9 total transactions. Robert Azelby's most active month to acquire stocks was the month of January. 2018 was Robert Azelby's most active year for disposing of shares, totalling 23 transactions. Robert Azelby's most active month to dispose stocks was the month of February. 2018 saw Robert Azelby paying a total of $6,215,553.80 for 1,190,821 shares, this is the most they've acquired in one year. In 2018 Robert Azelby cashed out on 627,501 shares for a total of $12,442,231.10, their largest year based on trade value.